<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fetal growth restriction: Evaluation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fetal growth restriction: Evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fetal growth restriction: Evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Giancarlo Mari, MD, MBA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fetal growth restriction (FGR) is broadly defined as an estimated fetal weight (EFW) or abdominal circumference (AC) &lt;10<sup>th</sup> percentile for gestational age. Severe FGR is generally defined as an EFW or AC &lt;3<sup>rd</sup> percentile for gestational age; the presence of fetal umbilical artery (UA) Doppler abnormalities also suggests that FGR is severe. However, sonographic criteria for diagnosis of FGR vary  (<a class="graphic graphic_table graphicRef139438" href="/d/graphic/139438.html" rel="external">table 1</a>) [<a href="#rid1">1-3</a>]. None of these criteria is ideal for identification of FGR as all have poor performance for predicting adverse neonatal outcome [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/6752.html" rel="external">"Fetal growth restriction: Screening and diagnosis", section on 'Diagnosis'</a>.)</p><p>Identification of FGR is an integral component of prenatal care as it is a leading cause of perinatal morbidity and mortality [<a href="#rid5">5</a>]. When FGR is suspected, the obstetric provider needs to confirm the suspected diagnosis, determine the probable cause, assess the severity, counsel the parents, closely monitor fetal growth and well-being for the remainder of the pregnancy, and determine the optimal time for and route of birth. Although FGR is not a homogeneous entity, uteroplacental insufficiency with suboptimal fetal nutrition and hypoperfusion is a common pathway to many forms of FGR. It can be present in patients with pregnancy-associated hypertension, chronic hypertension, chronic kidney disease, maternal or fetal infection, diabetes with vasculopathy, and fetal aneuploidy. In these cases, the fetus is closely monitored to identify those who are at highest risk of perinatal demise and thus may benefit from early delivery.</p><p>This topic will discuss the evaluation of FGR in singleton pregnancies. Pregnancy management and outcome are reviewed separately. (See  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome"</a>.) </p><p>FGR in twin pregnancies is also reviewed separately. (See  <a class="medical medical_review" href="/d/html/130561.html" rel="external">"Twin pregnancy: Routine prenatal care", section on 'Screening for fetal growth restriction and discordance'</a> and  <a class="medical medical_review" href="/d/html/120803.html" rel="external">"Selective fetal growth restriction in monochorionic twin pregnancies"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INITIAL EVALUATION</span><span class="headingEndMark"> — </span>The diagnosis of FGR is established sonographically (see  <a class="medical medical_review" href="/d/html/6752.html" rel="external">"Fetal growth restriction: Screening and diagnosis"</a>). The pregnancy is then evaluated to determine whether fetal growth is impaired as a result of maternal, fetal, or placental processes  (<a class="graphic graphic_table graphicRef99966" href="/d/graphic/99966.html" rel="external">table 2</a>). However, this determination cannot always be made antenatally, despite the following evaluation. When no maternal and/or fetal predisposing factors are found, FGR may be termed idiopathic or isolated [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H3955727457"><span class="h2">Size percentile</span><span class="headingEndMark"> — </span>Fetuses &lt;3<sup>rd</sup> percentile are at greatest risk of adverse outcome. Most fetuses with EFW or AC between the 5<sup>th</sup> and 10<sup>th</sup> percentiles are constitutionally small and thus have normal neonatal outcomes [<a href="#rid8">8,9</a>]. However, they still need to be monitored closely because a proportion are FGR and at increased risk of adverse outcome.</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based retrospective cohort study composed of all singleton term pregnancies in Scotland between 1992 and 2008, the overall association between birth weight percentile and risk of perinatal death had a reverse J-shaped distribution [<a href="#rid10">10</a>]. Birth weight &lt;3<sup>rd</sup> percentile had the highest relative risk of antepartum stillbirth and the absolute risk of stillbirth in this group was approximately 1 in 100. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 834 prenatally suspected FGR cases, composite neonatal morbidity at &lt;5<sup>th</sup> percentile was 29 percent versus 15 percent at the 5<sup>th</sup> to 9<sup>th</sup> percentile (adjusted odds ratio 2.22, 95% CI 1.34-3.67) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Prospective Observational Trial to Optimize Pediatric Health (PORTO), which included over 1100 nonanomalous fetuses with EFW &lt;10<sup>th</sup> percentile at 24+0 to 36+6 weeks of gestation, only 2 percent of those at the 3<sup>rd</sup> to 10<sup>th</sup> percentile (5 of 254) experienced adverse perinatal outcome, while 6.2 percent of those &lt;3<sup>rd</sup> percentile (51 of 826) had an adverse outcome and all eight mortalities were in this group [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H1922139127"><span class="h2">Maternal history and physical examination</span><span class="headingEndMark"> — </span>The medical and obstetric history and physical examination help to identify maternal factors that have been associated with restricted fetal growth  (<a class="graphic graphic_table graphicRef99966" href="/d/graphic/99966.html" rel="external">table 2</a>).</p><p>Maternal characteristics have a major influence on fetal growth potential. For example, when race/ethnicity was taken into account, the 5<sup>th</sup> percentiles for White, Hispanic, Black, and Asian populations at 39 weeks of gestation were 2790, 2633, 2622, and 2621 grams, respectively, in a prospective study of over 2300 healthy individuals with low-risk, singleton pregnancies from 12 medical centers in the United States [<a href="#rid11">11</a>]. Using biometric standards derived solely from the group of fetuses from the White population, as many as 15 percent of the fetuses from other groups would have been classified as growth restricted (&lt;5<sup>th</sup> percentile).</p><p>Although pregnancy-associated hypertensive disorders are commonly considered causal factors, a study by the National Institute of Child Health and Human Development (NICHD) found that only preeclampsia with severe features, particularly with onset &lt;34 weeks of gestation, was associated with a significant and consistent impairment in fetal growth compared with normotensive pregnancies [<a href="#rid12">12</a>]. Growth impairment was observed as early as 22 to 23 weeks of gestation and could precede the characteristic maternal findings defining the disorder.</p><p class="headingAnchor" id="H418922768"><span class="h2">Fetal anatomic survey</span><span class="headingEndMark"> — </span>A detailed fetal anatomic survey should be performed in all cases since approximately 10 percent of FGR is associated with congenital anomalies [<a href="#rid13">13</a>] and 20 to 60 percent of anomalous infants are small for gestational age [<a href="#rid14">14</a>]. These anomalies include omphalocele, gastroschisis, diaphragmatic hernia, skeletal dysplasia, some congenital heart abnormalities, and rarely congenital portosystemic shunts [<a href="#rid15">15</a>]. Although omphalocele and gastroschisis can be associated with FGR, the AC is distorted by the anomaly in these cases, limiting the utility of biometric measurements for diagnosis of FGR. </p><p>A fetal echocardiogram is indicated if there is uncertainty about normal cardiac development on a detailed ultrasound examination. </p><p class="headingAnchor" id="H3121250725"><span class="h2">Selective work-up for genetic abnormalities</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for genetic studies</strong> – We suggest offering fetal genetic testing to patients in any of the following settings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FGR before 32 weeks in the absence of an identifiable nongenetic cause of the growth restriction. After 32 weeks, fetal genetic testing is typically not performed when anatomy is normal since the risk of aneuploidy is low [<a href="#rid16">16-18</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FGR with major fetal structural abnormalities or ultrasound markers associated with an increased risk of aneuploidy, such as a thickened nuchal fold.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FGR with polyhydramnios.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ultrasound findings suggestive of a triploid pregnancy. </p><p></p><p class="bulletIndent1">This approach generally aligns with that of the American College of Obstetricians and Gynecologists (ACOG), which suggests genetic counseling and offering diagnostic testing for patients with a diagnosis of FGR before 32 weeks or FGR in combination with polyhydramnios or fetal malformation [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing modality</strong> – Genetic counseling is useful in helping patients understand the benefits, risks, and limitations of the various genetic testing modalities, including whether to begin with a noninvasive screening test (cell-free DNA [cfDNA]) or a diagnostic test that requires amniocentesis, and when to pursue advanced genetic testing (exome and whole genome sequencing). In the author's practice, patients with nonanomalous FGR are counseled by a maternal-fetal medicine specialist and a genetic counselor. If the patient chooses to undergo amniocentesis, the author favors chromosomal microarray analysis. If the microarray analysis is nondiagnostic, performing additional genetic testing is controversial; however, exome and whole genome sequencing are promising approaches.</p><p></p><p class="bulletIndent1">Genetic testing modalities include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cell-free DNA of maternal blood – Cell-free DNA (cfDNA) is a screening test for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and selected sex chromosome aneuploidies. It has the advantage of being noninvasive, but it is not diagnostic. Test performance is reviewed separately. (See  <a class="medical medical_review" href="/d/html/458.html" rel="external">"Prenatal screening for common aneuploidies using cell-free DNA"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Microarray or karyotype – Microarray or karyotype is performed on cells in amniotic fluid obtained by amniocentesis. Compared with a karyotype, microarray analysis has a higher diagnostic yield as it detects both aneuploidy and microdeletions and duplications, thus it can improve the detection of genetic anomalies, especially in fetuses with nonanomalous FGR [<a href="#rid19">19,20</a>]. In a meta-analysis to estimate the incremental yield of microarray analysis over karyotyping in FGR, microarray had a 4 percent (95% CI 1-6) incremental yield in nonanomalous FGR and a 10 percent (95% CI 6-14) incremental yield in FGR with associated anomalies [<a href="#rid21">21</a>]. The most common pathogenic copy number variants in growth restricted fetuses were 22q11.1 duplication, Xp22.3 deletion, and 7q11.23 deletion. (See  <a class="medical medical_review" href="/d/html/16683.html" rel="external">"Prenatal diagnosis of chromosomal imbalance: Chromosomal microarray"</a>.) </p><p></p><p class="bulletIndent2">Microarray or karyotype can also be performed on trophoblast obtained by chorionic villus sampling (CVS); however, this test is typically restricted to first-trimester pregnancies and thus before a diagnosis of FGR is typically made. Although CVS will detect confined placental mosaicism (CPM), we do not perform placental biopsy in the second or third trimester to identify this abnormality antepartum because antenatal diagnosis of CPM would not change pregnancy management and the procedure is associated with a small risk of pregnancy complications.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exome and whole genome sequencing – The appropriate use of exome and whole genome sequencing in FGR without anatomic abnormalities is under investigation. In a prospective study of 19 small-for-gestational-age newborns without a known cause and with normal karyotype and microarray, three were subsequently found to have a genetic cause with whole genome sequencing [<a href="#rid22">22</a>]. In a meta-analysis of prospective and retrospective studies, prenatal exome sequencing had 4 percent incremental yield over karyotype or microarray in isolated FGR (7 diagnoses in 70 cases with exome sequencing versus 4 diagnoses in 70 cases with standard karyotype/microarray; pooled risk difference 0.04, 95% CI -0.05-0.12), but was much more informative (30 percent incremental yield) in cases with multisystem anomalies (23 diagnoses in 48 cases with exome sequencing versus 9 diagnoses in 48 cases with standard karyotype/microarray; pooled risk difference 0.30, 95% CI 0.13-0.47), and especially in fetuses with skeletal abnormalities (short long bones and other signs suggestive of skeletal dysplasia) [<a href="#rid23">23</a>]. Another meta-analysis reported exome sequencing had a 12 percent incremental yield in isolated FGR [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic causes of FGR</strong> – Genetic causes of FGR are listed in the table  (<a class="graphic graphic_table graphicRef139439" href="/d/graphic/139439.html" rel="external">table 3</a>) and selectively discussed in more detail below:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aneuploidy – In a systematic review, the risk of chromosomal abnormalities in apparently isolated FGR was 6.4 percent [<a href="#rid16">16</a>]. Trisomy 21 and 18 accounted for five and three cases, respectively, of the 22 cases with numeric abnormalities. However, the authors emphasized that the small number of cases and low quality of evidence limited an accurate estimate for chromosomal abnormalities in pregnancies with isolated FGR. Others have also reported an increased risk of FGR in trisomy 21 pregnancies without severe structural anomalies [<a href="#rid25">25</a>] and with trisomy 13 [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent2">Triploidy of paternal origin (diandric) is characterized by symmetric FGR with associated structural abnormalities in most cases and an enlarged placenta with hydropic and cystic changes (often a partial mole) [<a href="#rid17">17,18</a>]. Triploidy of maternal origin (digynic) is nonmolar and characterized by asymmetric FGR and a small placenta; holoprosencephaly may be present. Both types of triploidy may have oligohydramnios and abnormal Doppler velocimetry [<a href="#rid18">18</a>]. Fetuses with digynic triploidy are more likely to survive to the second trimester than those with diandric triploidy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monogenic disorders – Fetuses with FGR related to monogenic disorders (eg, Cornelia de Lange, Smith-Lemli-Opitz, Meier-Gorlin, Noonan syndromes [<a href="#rid26">26</a>]) often have other findings, including thickened nuchal fold, congenital heart disease, and limb reduction defects. The pediatric outcome is often due to the abnormalities present in each case, and neurodevelopment may be either normal or show moderate to severe intellectual disability.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Confined placental mosaicism – CPM increases the risk for FGR at least three-fold [<a href="#rid27">27</a>] and is present in about 10 percent of cases with unexplained FGR [<a href="#rid28">28,29</a>]. CPM of chromosomes 2, 7-10, 13-18, 21, and 22 is disproportionately found in FGR fetuses. CPM for trisomy 16 deserves special consideration as it is estimated to complicate approximately 1 percent of all pregnancies and is associated with FGR in 43 to 58 percent of cases [<a href="#rid18">18</a>]. It has also been associated with fetal malformations, preeclampsia, and preterm birth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Uniparental disomy – Genes related to fetal growth are differentially expressed depending on the parent of origin. Imprinted genes control placental development, nutrient exchange, and growth rate. Uniparental disomy is rare and can lead to dysregulation of imprinted genes. The most common of these is uniparental disomy of chromosome 7 leading to Silver-Russell syndrome. Other causes are listed in the table  (<a class="graphic graphic_table graphicRef139439" href="/d/graphic/139439.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Epigenetic changes – Although epigenetic changes (modification of gene expression rather than differences in the DNA coding sequence) are emerging as key regulators of placental function, methods and utility of clinical testing for these changes as a cause of FGR remain investigational. Many cases of Silver-Russell syndrome are due to epigenetic alterations involving hypomethylation of an imprinting control region that regulates expression of the insulin-like growth factor 2 gene or others on 11p15.5 chromosome.</p><p></p><p class="headingAnchor" id="H2941318329"><span class="h2">Selective work-up for infection</span><span class="headingEndMark"> — </span>The author obtains serology studies for infection when FGR is associated with sonographic markers of fetal infection (echogenicity and calcification of the brain and/or liver, hydrops) or when a careful maternal history and physical examination suggest the possibility of maternal infection and vertical transmission. He does not perform routine TORCH serology in the evaluation of isolated FGR. If the patient chooses to have diagnostic fetal infection testing for isolated FGR, he performs amniocentesis for polymerase chain reaction (PCR) of amniotic fluid for cytomegalovirus (CMV). In patients who live in or travel to areas where malaria is endemic, malaria should be considered a possible etiology of FGR and excluded (see  <a class="medical medical_review" href="/d/html/4795.html" rel="external">"Malaria in pregnancy: Epidemiology, clinical manifestations, diagnosis, and outcome"</a>). Similarly, in patients at increased risk for Zika virus infection, congenital Zika virus infection should be considered a possible etiology of FGR and excluded (see  <a class="medical medical_review" href="/d/html/107211.html" rel="external">"Zika virus infection: Evaluation and management of pregnant patients"</a>). Screening for syphilis one or more times is a routine prenatal test recommended for all pregnant patients. In a literature review of 161 cases of congenital syphilis, 23 (14 percent) had FGR. (See  <a class="medical medical_review" href="/d/html/4794.html" rel="external">"Syphilis in pregnancy", section on 'Candidates and timing of initial and repeat screening'</a>.)</p><p>Although infections such as CMV, toxoplasmosis, rubella, varicella, and herpes simplex may be associated with FGR (refer to individual topic reviews on specific fetal infections during pregnancy for a description of the ultrasound findings), use of maternal serology should be limited because, when positive, the time of occurrence of the primary infection is often difficult to determine. This may lead to unnecessary invasive procedures with associated parental anxiety and cost. Due to its low yield, the Society for Maternal-Fetal Medicine recommends against TORCH serology for isolated FGR and recommends PCR of amniotic fluid for CMV in patients with unexplained FGR who elect to have diagnostic testing [<a href="#rid1">1</a>]. In a systematic review including 2538 pregnancies in eight studies, 496 TORCH serologies were performed in patients with FGR (EFW &lt;10<sup>th</sup> percentile) [<a href="#rid30">30</a>]. Of this group, 12 were positive (2.4 percent, 95% CI 1.4-4.2%) and 10 congenital infections were detected (eight CMV, two parvovirus B19), but only 2 of the 10 fetuses had isolated FGR (CMV infection was found in both cases). The studies included in this review did not differentiate between early and late FGR (ie, onset &lt;32 versus ≥32 weeks) and there were no cases of rubella or herpes simplex virus.</p><p>Maternal COVID-19 does not appear to be associated with an increased risk of FGR [<a href="#rid31">31,32</a>]. However, data on perinatal outcomes when the infection is acquired in early pregnancy are limited, and any condition that results in prolonged maternal hypoxia or placental dysfunction places the fetus at risk for growth restriction. (See  <a class="medical medical_review" href="/d/html/2282.html" rel="external">"The placental pathology report", section on 'Chronic histiocytic intervillositis'</a>.) </p><p class="headingAnchor" id="H4214057562"><span class="h2">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span>Routinely testing for antiphospholipid antibodies is not recommended as there is insufficient evidence to support evaluating all pregnancies with FGR for antiphospholipid antibody syndrome (APS). Early-onset placental insufficiency (eg, FGR) with birth before 34 weeks of gestation is one of the clinical criteria for the diagnosis of APS by expert consensus  (<a class="graphic graphic_table graphicRef104569" href="/d/graphic/104569.html" rel="external">table 4</a>) [<a href="#rid33">33</a>]. Testing for antiphospholipid antibodies in patients with this obstetric history has been suggested for those who also manifest livedo, valvular heart disease, neurologic findings such as cognitive deficits and white matter lesions, a systemic autoimmune disease (especially systemic lupus erythematosus) with appropriate clinical symptoms, and/or laboratory abnormalities such as otherwise unexplained mild thrombocytopenia, prolongation of the activated partial thromboplastin time (aPTT), or a history of a false-positive serologic test for syphilis (Venereal Disease Research Laboratory [VDRL] or rapid plasma reagin [RPR] tests). (See  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome", section on 'When to suspect the diagnosis'</a> and  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/6813.html" rel="external">"Antiphospholipid syndrome: Obstetric implications and management in pregnancy", section on 'Adverse pregnancy outcomes defining APS'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment for inherited thrombophilic disorders is not recommended as evidence of an association between the inherited thrombophilias and FGR is weak. (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Adverse pregnancy outcome risk'</a>.)</p><p></p><p class="headingAnchor" id="H10977003"><span class="h1">SUBSEQUENT EVALUATION</span><span class="headingEndMark"> — </span>After the initial evaluation, additional assessments are performed over time to help distinguish the fetus at increased risk of adverse outcome from the constitutionally small fetus or the fetus who is minimally impacted from a placenta-mediated disorder or other pathologic factors that impair fetal growth and at low risk of adverse outcome. The modalities are described below; our approach to obtaining these assessments and managing the pregnancy based on the findings is provided separately. (See  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome"</a>.)</p><p class="headingAnchor" id="H3556718872"><span class="h2">Fetal weight</span><span class="headingEndMark"> — </span>Fetal weight is calculated using various published equations and formulae. Most clinicians use the Hadlock formula [<a href="#rid34">34</a>]. The computed EFW is then compared with Hadlock standards for fetal weight across gestation or plotted on a population-based or customized growth curve [<a href="#rid35">35</a>]. The rate of adverse perinatal outcomes are inversely related to the percentile [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H3335866704"><span class="h2">Doppler velocimetry</span><span class="headingEndMark"> — </span>The hemodynamic physiology of FGR is the basis for the use of Doppler ultrasound to monitor and manage affected pregnancies. The classic progressive sequence of Doppler changes in the peripheral and central circulatory systems leading to fetal compromise or death in FGR are shown in the figure  (<a class="graphic graphic_figure graphicRef73075" href="/d/graphic/73075.html" rel="external">figure 1</a>) but other patterns of Doppler deterioration also exist [<a href="#rid6">6,37-40</a>]. This sequence is most likely to progress quickly (within days) when the onset of FGR is earlier in gestation and with increasing severity of placental insufficiency [<a href="#rid41">41</a>]. Doppler abnormalities in late gestational FGR may progress slowly (within weeks) or not at all or along a different pathway [<a href="#rid38">38</a>]. The reason is that FGR is not a homogeneous entity and different phenotypes of FGR behave differently. For example, FGR associated with preeclampsia with severe features may have a different clinical course from idiopathic FGR [<a href="#rid7">7</a>].</p><p>The following figures  (<a class="graphic graphic_figure graphicRef132200" href="/d/graphic/132200.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef132201" href="/d/graphic/132201.html" rel="external">figure 3</a>) compare the Doppler changes observed from the time of initial diagnosis of FGR until delivery or fetal demise in a series of pregnancies with idiopathic FGR versus those with FGR associated with preeclampsia diagnosed at &lt;32 weeks of gestation. It is important to emphasize that not all fetal vessels reported in the figures are used in current clinical practice. (See  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome", section on 'Doppler ultrasonography, nonstress test/cardiotocography, and biophysical profile'</a>.)</p><p class="headingAnchor" id="H2326620697"><span class="h3">Umbilical artery Doppler</span><span class="headingEndMark"> — </span>UA Doppler is the primary surveillance tool for monitoring pregnancies with FGR [<a href="#rid1">1,3,19,42</a>]. UA diastolic flow normally increases with advancing gestational age  (<a class="graphic graphic_waveform graphicRef132202" href="/d/graphic/132202.html" rel="external">waveform 1</a>). UA indices become abnormal when 30 percent of the placental villous vasculature is damaged by embolization [<a href="#rid43">43</a>]. When 60 to 70 percent of the placental villous vasculature is obliterated, flow in the UA can become absent or even reversed at the end of the cardiac cycle  (<a class="graphic graphic_waveform graphicRef132203" href="/d/graphic/132203.html" rel="external">waveform 2</a>) [<a href="#rid44">44</a>].</p><p>The most common UA Doppler indices used in clinical obstetric practice are:</p><p class="bulletIndent1"><span class="glyph">●</span>Pulsatility index (PI = peak systolic velocity - end-diastolic velocity/time-averaged maximum velocity) [<a href="#rid45">45</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Resistance index (RI = peak systolic velocity – end-diastolic velocity/peak systolic velocity) [<a href="#rid46">46</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>S/D ratio: Peak systolic velocity/end-diastolic velocity [<a href="#rid47">47</a>]</p><p></p><p>Reference ranges for the three UA indices have been reported in many studies, including a longitudinal study [<a href="#rid48">48</a>]. The PI is preferred because it gives a better estimate of the characteristics of the waveform than the RI or S/D ratio [<a href="#rid49">49</a>]. A value above the 95<sup>th</sup> percentile for gestational age is considered abnormal.</p><p>The severity of UA Doppler abnormalities correlates with prognosis: Reversed diastolic flow is associated with fivefold higher perinatal mortality compared with absent flow [<a href="#rid50">50</a>]. Numerous randomized trials and well-designed observational studies have established that monitoring UA Doppler can significantly reduce perinatal death by prompting early delivery when it is abnormal. In addition, a normal Doppler is infrequently associated with significant perinatal morbidity or mortality and is strong evidence of fetal well-being; thus, this finding provides support for delaying delivery of preterm gestations when it is important to gain further fetal maturity.</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of 19 trials comparing the use of mostly UA Doppler with no Doppler in over 10,000 high-risk pregnancies, Doppler use reduced perinatal deaths (1.2 versus 1.7 percent; risk ratio [RR] 0.71, 95% CI 0.52-0.98; number needed to treat 203), labor induction (RR 0.89, 95% CI 0.80-0.99) and cesarean births (RR 0.90, 95% CI 0.84-0.97) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Prospective Observational Trial to Optimize Pediatric Health in FGR (PORTO) study, FGR with normal UA Doppler was associated with less perinatal mortality than FGR with abnormal Doppler (2 of 698 [0.3 percent] versus 6 of 418 [1.4 percent]) and a lower rate of overall adverse outcome (9 of 698 [1.3 percent] versus 48 of 418 [11.5 percent]) [<a href="#rid8">8,52</a>]. In addition, the combination of EFW &lt;3<sup>rd</sup> percentile and abnormal UA Doppler was a strong and consistent predictor of adverse outcome: 16.7 percent of these fetuses developed intraventricular hemorrhage, periventricular leukomalacia, hypoxic ischemic encephalopathy, necrotizing enterocolitis, bronchopulmonary dysplasia, sepsis, or death. Abnormal UA Doppler was defined as a pulsatility index (PI) &gt;95<sup>th</sup> percentile or absent/reversed end-diastolic flow.</p><p></p><p>A detailed discussion of Doppler interrogation of the UA, including performance of the test, is available separately. (See  <a class="medical medical_review" href="/d/html/459.html" rel="external">"Doppler ultrasound of the umbilical artery for fetal surveillance in singleton pregnancies"</a>.) </p><p class="headingAnchor" id="H2621407748"><span class="h3">Middle cerebral artery pulsatility index</span><span class="headingEndMark"> — </span>In uncomplicated pregnancies, vascular resistance of the fetal brain changes with advancing gestation, thus the middle cerebral artery (MCA) PI is low at early gestational ages (&lt;20 weeks), then gradually increases, before gradually decreasing in the third trimester [<a href="#rid53">53,54</a>].<strong> </strong>However, in fetuses such as those with FGR experiencing progressive hypoxemia, cerebral blood flow increases to compensate for the decrease in available oxygen (brain-sparing effect)  (<a class="graphic graphic_waveform graphicRef139440" href="/d/graphic/139440.html" rel="external">waveform 3</a>) [<a href="#rid55">55</a>], which results in a reduction in MCA PI [<a href="#rid6">6,7,37,39,40</a>]. Subsequent normalization of the MCA PI may occur and is considered an ominous sign because it indicates the loss of brain-sparing [<a href="#rid56">56</a>].</p><p>The MCA PI can be the first parameter to become abnormal in late FGR [<a href="#rid57">57</a>], followed by the UA PI. An abnormal MCA PI is found in approximately 20 percent of FGR cases with normal UA PI in the third trimester [<a href="#rid58">58,59</a>] and associated with a higher incidence of suboptimal neurodevelopmental outcome at two years of age compared with a normal MCA PI [<a href="#rid58">58</a>]. In a study of 856 FGR cases between 32 and 36.6 weeks, an abnormal MCA PI (&lt;5<sup>th</sup> percentile for gestational age) had higher relative risk of a composite adverse outcome compared with the UA PI [<a href="#rid60">60</a>]. Two fetuses died; in both cases, UA PI was normal while MCA PI was abnormal.</p><p>MCA Doppler results can be used to calculate two ratios sometimes used in the evaluation of FGR. (See <a class="local">'Cerebroplacental ratio'</a> below and <a class="local">'Umbilicocerebral ratio'</a> below.)</p><p class="headingAnchor" id="H1768964089"><span class="h3">Ductus venosus Doppler</span><span class="headingEndMark"> — </span>Normal flow in the fetal ductus venous (DV) is forward and uniform [<a href="#rid61">61</a>]. With progressively increasing UA resistance in FGR, fetal cardiac performance becomes impaired and atrial pressure increases, resulting in reduced diastolic flow in the DV a-wave. With progression of the severity of FGR, and late in the course of the disorder, the a-wave becomes absent or reversed  (<a class="graphic graphic_waveform graphicRef139441" href="/d/graphic/139441.html" rel="external">waveform 4</a>) [<a href="#rid6">6,7,37,39,40</a>]. Absent or reversed DV a-wave is considered a sign of impending acidemia and fetal demise. It has overall sensitivity of 65 percent and specificity of 95 percent for fetal pH &lt;7.20 [<a href="#rid62">62</a>]. The time from detection of absent or reversed DV a-wave to delivery or fetal demise is variable, and not all very preterm FGR fetuses with this finding are acidemic [<a href="#rid63">63</a>]. Neither neonatal death nor neonatal morbidity are predicted by its duration [<a href="#rid64">64</a>].</p><p>Absent or reversed a-wave is uncommon, occurs more often in early that late FGR, and typically is seen after reversed flow in the UA has been observed.</p><p class="headingAnchor" id="H2706127212"><span class="h2">Biophysical profile and nonstress test/cardiotocography</span><span class="headingEndMark"> — </span>Both the nonstress test (NST; also called cardiotocography [CTG]) with amniotic fluid volume determination and the biophysical profile (BPP) are used to monitor fetal status as these tests evaluate both acute and chronic fetal physiologic parameters [<a href="#rid19">19,42</a>]. The tests are relatively easy to perform and are initiated at a gestational age at which an abnormal finding would trigger intervention. The frequency of testing is determined by UA Doppler results and amniotic fluid volume. Normal results in conjunction with normal UA Doppler velocimetry has been associated with improved outcomes in pregnancies with FGR. (See  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome", section on 'Doppler ultrasonography, nonstress test/cardiotocography, and biophysical profile'</a>.)</p><p>The rationale for including a BPP in FGR management is based on its superior reflection of current fetal acid-base balance, which is independent of fetal heart rate testing and multivessel Doppler [<a href="#rid65">65</a>]. It is important to note that the BPP is not used in many countries outside of the United States and the use of computerized cardiotocography (cCTG) rather than conventional CTG for fetal heart rate monitoring and interpretation is used in many of these countries [<a href="#rid3">3</a>]. Specific concerns about the BPP in FGR surveillance are based on a Cochrane review that concluded that there is insufficient evidence from randomized trials to support the use of BPP as a test of fetal well-being in high-risk pregnancies [<a href="#rid66">66</a>]; however, the analysis mainly included high-risk pregnancies with conditions other than FGR and did not assess acidemia and stillbirth rates in relation to surveillance strategy. In an observational study specifically evaluating use of the BPP in managing early severe FGR (&lt;1000 g), a normal BPP score did not predict the outcome in the next 24 hours of this subgroup of FGR pregnancies [<a href="#rid67">67</a>], underscoring the importance of using multiple modalities for fetal surveillance and frequent (eg, three times daily) testing.</p><p>Similar to the BPP, there has been no randomized trial of the NST in FGR management and no study showing that the NST is superior to the BPP (or vice versa) for the management of FGR. Between 30 and 70 percent of cases of FGR with a nonreactive NST require a BPP to verify fetal well-being. The BPP score is abnormal in 8 to 27 percent of these cases and identifies the need for delivery, which was not suspected by Doppler findings [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H2981332874"><span class="h2">Other evaluations</span></p><p class="headingAnchor" id="H2004150960"><span class="h3">Growth velocity</span><span class="headingEndMark"> — </span>The diagnosis of FGR on a single ultrasound based on an EFW &lt;5<sup>th</sup> percentile in a well-dated pregnancy, oligohydramnios, and abnormal Doppler indices does not require serial scans for confirmation; however, assessing growth velocity (trajectory) has the potential to assist in the diagnosis of less severe forms of FGR not captured by current diagnostic criteria [<a href="#rid2">2,68-74</a>]. A normal growth velocity (ie, parallel to the growth curve of fetuses with EFW or AC &gt;10<sup>th</sup> percentile) appears to be predictive of a favorable outcome, while an abnormal growth velocity (a percentile drop between consecutive ultrasound scans of <em>&gt;</em>50 percentiles in EFW or AC [eg, from the 75<sup>th</sup> percentile to the 20<sup>th</sup> percentile]) appears to predict perinatal complications (eg, preterm birth, preeclampsia, neonatal morbidity). </p><p>The author does not routinely calculate growth velocity as studies have not established that determination of growth velocity substantially improves prediction of birthweight and perinatal outcome (morbidity and mortality) compared with EFW alone. Routine fetal growth velocity assessment is not endorsed by the American College of Obstetrics and Gynecology, Society for Maternal-Fetal Medicine, and American Institute of Ultrasound in Medicine (AIUM) for management of pregnancies affected by FGR [<a href="#rid1">1,19</a>] .</p><p class="headingAnchor" id="H2803798392"><span class="h3">Cerebroplacental ratio</span><span class="headingEndMark"> — </span>The cerebroplacental ratio (CPR) is the MCA PI divided by UA PI [<a href="#rid75">75</a>]. The CPR reflects both the placental status and fetal response and thus may be a sensitive Doppler index for predicting perinatal outcome [<a href="#rid76">76</a>]. In late-onset FGR, reduction in the CPR may be the only Doppler change present [<a href="#rid77">77</a>]. However, the clinical value of this ratio has not been established, in part because studies have used different threshold values for predicting adverse outcome (CPR &lt;1, &lt;1.05, ≤1.08, &lt;5<sup>th</sup> percentile) [<a href="#rid78">78-85</a>]. </p><p>More data are needed to determine whether CPR should be used in clinical practice to monitor FGR.</p><p class="headingAnchor" id="H36238653"><span class="h3">Umbilicocerebral ratio</span><span class="headingEndMark"> — </span>The umbilicocerebral ratio (UCR) is the MCA PI divided by UA PI. As fetal Doppler changes become increasingly abnormal with lower MCA and higher UA impedance, CPR tends toward zero whereas the UCR tends toward infinity [<a href="#rid60">60</a>]. The UCR may allow for better differentiation of Doppler abnormalities than the CPR; however, the clinical value of this ratio has not been established.</p><p>More data are needed to determine whether UCR should be used in clinical practice to monitor FGR. A randomized trial is underway in the Netherlands to compare outcomes of immediate induction versus expectant management of FGR with abnormal UCR (defined as &gt;0.8) [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H962081811"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120349.html" rel="external">"Society guideline links: Fetal growth restriction"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Identification of fetal growth restriction (FGR) is an integral component of prenatal care as it is a leading cause of perinatal morbidity and mortality. When FGR is suspected, the obstetric provider needs to confirm the suspected diagnosis, determine the probable cause, assess the severity, counsel the parents, closely monitor fetal growth and well-being for the remainder of the pregnancy, and determine the optimal time for and route of birth. Although FGR is not a homogeneous entity, uteroplacental insufficiency with suboptimal fetal nutrition and hypoperfusion is a common pathway to many forms of FGR. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – Sonographic criteria for diagnosis of FGR vary  (<a class="graphic graphic_table graphicRef139438" href="/d/graphic/139438.html" rel="external">table 1</a>). After diagnosis of FGR, the pregnancy is evaluated to determine whether fetal growth is impaired as a result of maternal, fetal, or placental processes  (<a class="graphic graphic_table graphicRef99966" href="/d/graphic/99966.html" rel="external">table 2</a>). However, this determination cannot always be made antenatally.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Percentile</strong> – Fetuses &lt;3<sup>rd</sup> percentile are at greatest risk of adverse outcome. Most fetuses with estimated fetal weight (EFW) or abdominal circumference (AC) between the 5<sup>th</sup> and 10<sup>th</sup> percentiles are constitutionally small and thus have normal neonatal outcomes. However, they still need to be monitored closely because a proportion of these fetuses are FGR and at increased risk of adverse outcome. (See <a class="local">'Size percentile'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History and physical examination</strong> – The medical and obstetric history and physical examination help to assess for maternal factors that have been associated with FGR. (See <a class="local">'Maternal history and physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fetal anatomic survey</strong> – A detailed fetal anatomic survey is performed in all cases since approximately 10 percent of FGR is accompanied by congenital anomalies and 20 to 60 percent of anomalous infants are small for gestational age. (See <a class="local">'Fetal anatomic survey'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic testing</strong> – We offer fetal genetic diagnostic tests to patients in any of the following settings (See <a class="local">'Selective work-up for genetic abnormalities'</a> above.):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>FGR without a known cause diagnosed before 32 weeks. After 32 weeks, we do not screen for fetal genetic abnormalities if anatomy is normal since the risk of aneuploidy is more common early in gestation and the yield would be low.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>FGR with major fetal structural abnormalities or ultrasound markers associated with an increased risk of aneuploidy, such as a thickened nuchal fold.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>FGR with polyhydramnios.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Ultrasound findings suggestive of a triploid pregnancy.</p><p></p><p class="bulletIndent2">Issues to consider are use of a noninvasive screening test (cell-free DNA) or a diagnostic test (microarray or karyotype) that requires amniocentesis, and when to pursue advanced genetic testing (exome or whole genome sequencing).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory testing </strong>– We obtain serology studies for infection when FGR is associated with sonographic markers of fetal infection (echogenicity and calcification of the brain and/or liver, hydrops) or when a careful maternal history and physical examination suggest the possibility of maternal infection and vertical transmission. We do not perform routine TORCH serology in the evaluation of isolated FGR. (See <a class="local">'Selective work-up for infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent evaluation</strong> – After the initial evaluation, periodic assessment of fetal weight and Doppler interrogation of the umbilical artery (UA) are performed to distinguish the fetus at increased risk of adverse outcome from the constitutionally small fetus or a fetus that is minimally impacted from uteroplacental insufficiency or other pathologic factors that impair fetal growth and at low risk of adverse outcome. (See <a class="local">'Subsequent evaluation'</a> above and  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome"</a>.)</p><p></p><p class="headingAnchor" id="H484361628"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert Resnik, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM). Electronic address: <span class="__cf_email__" data-cfemail="adddd8cfdeeddec0cbc083c2dfca">[email protected]</span>, Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). Am J Obstet Gynecol 2020; 223:B2.</a></li><li><a class="nounderline abstract_t">Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 2016; 48:333.</a></li><li><a class="nounderline abstract_t">Lees CC, Stampalija T, Baschat A, et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol 2020; 56:298.</a></li><li><a class="nounderline abstract_t">Molina LCG, Odibo L, Zientara S, et al. Validation of Delphi procedure consensus criteria for defining fetal growth restriction. Ultrasound Obstet Gynecol 2020; 56:61.</a></li><li><a class="nounderline abstract_t">Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002; 99:490.</a></li><li><a class="nounderline abstract_t">Cosmi E, Ambrosini G, D'Antona D, et al. Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses. Obstet Gynecol 2005; 106:1240.</a></li><li><a class="nounderline abstract_t">Mari G, Hanif F, Kruger M. Sequence of cardiovascular changes in IUGR in pregnancies with and without preeclampsia. Prenat Diagn 2008; 28:377.</a></li><li><a class="nounderline abstract_t">Unterscheider J, Daly S, Geary MP, et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study. Am J Obstet Gynecol 2013; 208:290.e1.</a></li><li><a class="nounderline abstract_t">Mlynarczyk M, Chauhan SP, Baydoun HA, et al. The clinical significance of an estimated fetal weight below the 10th percentile: a comparison of outcomes of &lt;5th vs 5th-9th percentile. Am J Obstet Gynecol 2017; 217:198.e1.</a></li><li><a class="nounderline abstract_t">Moraitis AA, Wood AM, Fleming M, Smith GCS. Birth weight percentile and the risk of term perinatal death. Obstet Gynecol 2014; 124:274.</a></li><li><a class="nounderline abstract_t">Buck Louis GM, Grewal J, Albert PS, et al. Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies. Am J Obstet Gynecol 2015; 213:449.e1.</a></li><li><a class="nounderline abstract_t">Mateus J, Newman RB, Zhang C, et al. Fetal growth patterns in pregnancy-associated hypertensive disorders: NICHD Fetal Growth Studies. Am J Obstet Gynecol 2019; 221:635.e1.</a></li><li><a class="nounderline abstract_t">Mendez H. Introduction to the study of pre- and postnatal growth in humans: a review. Am J Med Genet 1985; 20:63.</a></li><li><a class="nounderline abstract_t">Khoury MJ, Erickson JD, Cordero JF, McCarthy BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics 1988; 82:83.</a></li><li><a class="nounderline abstract_t">Bardin R, Perlman S, Hadar E, et al. Fetal-TAPSE for Surveillance of Cardiac Function in Growth-Restricted Fetuses With a Portosystemic Shunt. J Ultrasound Med 2021; 40:2431.</a></li><li><a class="nounderline abstract_t">Sagi-Dain L, Peleg A, Sagi S. Risk for chromosomal aberrations in apparently isolated intrauterine growth restriction: A systematic review. Prenat Diagn 2017; 37:1061.</a></li><li><a class="nounderline abstract_t">Lugthart MA, Horenblas J, Kleinrouweler EC, et al. Prenatal sonographic features can accurately determine parental origin in triploid pregnancies. Prenat Diagn 2020; 40:705.</a></li><li><a class="nounderline abstract_t">Meler E, Sisterna S, Borrell A. Genetic syndromes associated with isolated fetal growth restriction. Prenat Diagn 2020; 40:432.</a></li><li><a class="nounderline abstract_t">Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. Obstet Gynecol 2021; 137:e16.</a></li><li><a class="nounderline abstract_t">Monier I, Receveur A, Houfflin-Debarge V, et al. Should prenatal chromosomal microarray analysis be offered for isolated fetal growth restriction? A French multicenter study. Am J Obstet Gynecol 2021; 225:676.e1.</a></li><li><a class="nounderline abstract_t">Borrell A, Grande M, Pauta M, et al. Chromosomal Microarray Analysis in Fetuses with Growth Restriction and Normal Karyotype: A Systematic Review and Meta-Analysis. Fetal Diagn Ther 2018; 44:1.</a></li><li><a class="nounderline abstract_t">Park SJ, Lee N, Jeong SH, et al. Genetic Aspects of Small for Gestational Age Infants Using Targeted-Exome Sequencing and Whole-Exome Sequencing: A Single Center Study. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Mone F, Mellis R, Gabriel H, et al. Should we offer prenatal exome sequencing for intrauterine growth restriction or short long bones? A systematic review and meta-analysis. Am J Obstet Gynecol 2023; 228:409.</a></li><li><a class="nounderline abstract_t">Pauta M, Martinez-Portilla RJ, Meler E, et al. Diagnostic yield of exome sequencing in isolated fetal growth restriction: Systematic review and meta-analysis. Prenat Diagn 2023; 43:596.</a></li><li><a class="nounderline abstract_t">Yao R, Contag SA, Goetzinger KR, et al. The role of fetal growth restriction in the association between Down syndrome and perinatal mortality. J Matern Fetal Neonatal Med 2020; 33:952.</a></li><li><a class="nounderline abstract_t">Nowakowska BA, Pankiewicz K, Nowacka U, et al. Genetic Background of Fetal Growth Restriction. Int J Mol Sci 2021; 23.</a></li><li><a class="nounderline abstract_t">Spinillo SL, Farina A, Sotiriadis A, et al. Pregnancy outcome of confined placental mosaicism: meta-analysis of cohort studies. Am J Obstet Gynecol 2022; 227:714.</a></li><li><a class="nounderline abstract_t">Wilkins-Haug L, Roberts DJ, Morton CC. Confined placental mosaicism and intrauterine growth retardation: a case-control analysis of placentas at delivery. Am J Obstet Gynecol 1995; 172:44.</a></li><li><a class="nounderline abstract_t">Stipoljev F, Latin V, Kos M, et al. Correlation of confined placental mosaicism with fetal intrauterine growth retardation. A case control study of placentas at delivery. Fetal Diagn Ther 2001; 16:4.</a></li><li><a class="nounderline abstract_t">Fitzpatrick D, Holmes NE, Hui L. A systematic review of maternal TORCH serology as a screen for suspected fetal infection. Prenat Diagn 2022; 42:87.</a></li><li><a class="nounderline abstract_t">Dashraath P, Wong JLJ, Lim MXK, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020; 222:521.</a></li><li><a class="nounderline abstract_t">Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020; 2:100107.</a></li><li><a class="nounderline abstract_t">Committee on Practice Bulletins—Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol 2012; 120:1514. Reaffirmed 2019.</a></li><li><a class="nounderline abstract_t">Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. Radiology 1991; 181:129.</a></li><li><a class="nounderline abstract_t">Duryea EL, Hawkins JS, McIntire DD, et al. A revised birth weight reference for the United States. Obstet Gynecol 2014; 124:16.</a></li><li><a class="nounderline abstract_t">Pilliod RA, Cheng YW, Snowden JM, et al. The risk of intrauterine fetal death in the small-for-gestational-age fetus. Am J Obstet Gynecol 2012; 207:318.e1.</a></li><li><a class="nounderline abstract_t">Hecher K, Bilardo CM, Stigter RH, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 2001; 18:564.</a></li><li><a class="nounderline abstract_t">Unterscheider J, Daly S, Geary MP, et al. Predictable progressive Doppler deterioration in IUGR: does it really exist? Am J Obstet Gynecol 2013; 209:539.e1.</a></li><li><a class="nounderline abstract_t">Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 2001; 18:571.</a></li><li><a class="nounderline abstract_t">Ferrazzi E, Bozzo M, Rigano S, et al. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. Ultrasound Obstet Gynecol 2002; 19:140.</a></li><li><a class="nounderline abstract_t">Turan OM, Turan S, Gungor S, et al. Progression of Doppler abnormalities in intrauterine growth restriction. Ultrasound Obstet Gynecol 2008; 32:160.</a></li><li><a class="nounderline abstract_t">Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828. Obstet Gynecol 2021; 137:e177.</a></li><li><a class="nounderline abstract_t">Giles WB, Trudinger BJ, Baird PJ. Fetal umbilical artery flow velocity waveforms and placental resistance: pathological correlation. Br J Obstet Gynaecol 1985; 92:31.</a></li><li><a class="nounderline abstract_t">Morrow RJ, Adamson SL, Bull SB, Ritchie JW. Effect of placental embolization on the umbilical arterial velocity waveform in fetal sheep. Am J Obstet Gynecol 1989; 161:1055.</a></li><li><a class="nounderline abstract_t">Gosling RG, Dunbar G, King DH, et al. The quantitative analysis of occlusive peripheral arterial disease by a non-intrusive ultrasonic technique. Angiology 1971; 22:52.</a></li><li class="breakAll">Pourcelot, L. Applications cliniques de l'examen Doppler. In: Ultrasonic Doppler velocimetry: application to blood flow studies in large vessels, 34, Peronneau, P (Eds), Paris 1975. p.213.</li><li><a class="nounderline abstract_t">Stuart B, Drumm J, FitzGerald DE, Duignan NM. Fetal blood velocity waveforms in normal pregnancy. Br J Obstet Gynaecol 1980; 87:780.</a></li><li><a class="nounderline abstract_t">Acharya G, Wilsgaard T, Berntsen GK, et al. Reference ranges for serial measurements of umbilical artery Doppler indices in the second half of pregnancy. Am J Obstet Gynecol 2005; 192:937.</a></li><li><a class="nounderline abstract_t">Bhide A, Acharya G, Baschat A, et al. ISUOG Practice Guidelines (updated): use of Doppler velocimetry in obstetrics. Ultrasound Obstet Gynecol 2021; 58:331.</a></li><li><a class="nounderline abstract_t">Vasconcelos RP, Brazil Frota Aragão JR, Costa Carvalho FH, et al. Differences in neonatal outcome in fetuses with absent versus reverse end-diastolic flow in umbilical artery Doppler. Fetal Diagn Ther 2010; 28:160.</a></li><li><a class="nounderline abstract_t">Alfirevic Z, Stampalija T, Dowswell T. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev 2017; 6:CD007529.</a></li><li><a class="nounderline abstract_t">O'Dwyer V, Burke G, Unterscheider J, et al. Defining the residual risk of adverse perinatal outcome in growth-restricted fetuses with normal umbilical artery blood flow. Am J Obstet Gynecol 2014; 211:420.e1.</a></li><li><a class="nounderline abstract_t">Mari G, Deter RL. Middle cerebral artery flow velocity waveforms in normal and small-for-gestational-age fetuses. Am J Obstet Gynecol 1992; 166:1262.</a></li><li><a class="nounderline abstract_t">Ciobanu A, Wright A, Syngelaki A, et al. Fetal Medicine Foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio. Ultrasound Obstet Gynecol 2019; 53:465.</a></li><li><a class="nounderline abstract_t">Wladimiroff JW, Tonge HM, Stewart PA. Doppler ultrasound assessment of cerebral blood flow in the human fetus. Br J Obstet Gynaecol 1986; 93:471.</a></li><li><a class="nounderline abstract_t">Mari G, Wasserstrum N. Flow velocity waveforms of the fetal circulation preceding fetal death in a case of lupus anticoagulant. Am J Obstet Gynecol 1991; 164:776.</a></li><li><a class="nounderline abstract_t">Lees CC, Romero R, Stampalija T, et al. Clinical Opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach. Am J Obstet Gynecol 2022; 226:366.</a></li><li><a class="nounderline abstract_t">Eixarch E, Meler E, Iraola A, et al. Neurodevelopmental outcome in 2-year-old infants who were small-for-gestational age term fetuses with cerebral blood flow redistribution. Ultrasound Obstet Gynecol 2008; 32:894.</a></li><li><a class="nounderline abstract_t">Cruz-Martinez R, Figueras F, Hernandez-Andrade E, et al. Changes in myocardial performance index and aortic isthmus and ductus venosus Doppler in term, small-for-gestational age fetuses with normal umbilical artery pulsatility index. Ultrasound Obstet Gynecol 2011; 38:400.</a></li><li><a class="nounderline abstract_t">Stampalija T, Thornton J, Marlow N, et al. Fetal cerebral Doppler changes and outcome in late preterm fetal growth restriction: prospective cohort study. Ultrasound Obstet Gynecol 2020; 56:173.</a></li><li><a class="nounderline abstract_t">Kiserud T, Eik-Nes SH, Blaas HG, Hellevik LR. Ultrasonographic velocimetry of the fetal ductus venosus. Lancet 1991; 338:1412.</a></li><li><a class="nounderline abstract_t">Baschat AA, Gembruch U, Weiner CP, Harman CR. Qualitative venous Doppler waveform analysis improves prediction of critical perinatal outcomes in premature growth-restricted fetuses. Ultrasound Obstet Gynecol 2003; 22:240.</a></li><li><a class="nounderline abstract_t">Picconi JL, Hanif F, Drennan K, Mari G. The transitional phase of ductus venosus reversed flow in severely premature IUGR fetuses. Am J Perinatol 2008; 25:199.</a></li><li><a class="nounderline abstract_t">Turan OM, Turan S, Berg C, et al. Duration of persistent abnormal ductus venosus flow and its impact on perinatal outcome in fetal growth restriction. Ultrasound Obstet Gynecol 2011; 38:295.</a></li><li><a class="nounderline abstract_t">Baschat AA, Galan HL, Lee W, et al. The role of the fetal biophysical profile in the management of fetal growth restriction. Am J Obstet Gynecol 2022; 226:475.</a></li><li><a class="nounderline abstract_t">Lalor JG, Fawole B, Alfirevic Z, Devane D. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev 2008; :CD000038.</a></li><li><a class="nounderline abstract_t">Kaur S, Picconi JL, Chadha R, et al. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh &lt;1000 g. Am J Obstet Gynecol 2008; 199:264.e1.</a></li><li><a class="nounderline abstract_t">Barker ED, McAuliffe FM, Alderdice F, et al. The role of growth trajectories in classifying fetal growth restriction. Obstet Gynecol 2013; 122:248.</a></li><li><a class="nounderline abstract_t">Salomon LJ, Alfirevic Z, Da Silva Costa F, et al. ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth. Ultrasound Obstet Gynecol 2019; 53:715.</a></li><li><a class="nounderline abstract_t">Deter RL. Evaluation of intrauterine growth retardation in the fetus and neonate: are simple-minded methods good enough? Ultrasound Obstet Gynecol 1995; 6:161.</a></li><li><a class="nounderline abstract_t">Owen P, Donnet ML, Ogston SA, et al. Standards for ultrasound fetal growth velocity. Br J Obstet Gynaecol 1996; 103:60.</a></li><li><a class="nounderline abstract_t">Wu T, Gong X, Zhao Y, et al. Fetal growth velocity references from a Chinese population-based fetal growth study. BMC Pregnancy Childbirth 2021; 21:688.</a></li><li><a class="nounderline abstract_t">Grantz KL, Kim S, Grobman WA, et al. Fetal growth velocity: the NICHD fetal growth studies. Am J Obstet Gynecol 2018; 219:285.e1.</a></li><li><a class="nounderline abstract_t">Grantz KL, Grewal J, Kim S, et al. Unified standard for fetal growth velocity: the Eunice Kennedy Shriver National Institute of Child Health and Human Development Fetal Growth Studies. Am J Obstet Gynecol 2022; 227:916.</a></li><li><a class="nounderline abstract_t">Romero R, Hernandez-Andrade E. Doppler of the middle cerebral artery for the assessment of fetal well-being. Am J Obstet Gynecol 2015; 213:1.</a></li><li><a class="nounderline abstract_t">Wladimiroff JW, vd Wijngaard JA, Degani S, et al. Cerebral and umbilical arterial blood flow velocity waveforms in normal and growth-retarded pregnancies. Obstet Gynecol 1987; 69:705.</a></li><li><a class="nounderline abstract_t">Oros D, Figueras F, Cruz-Martinez R, et al. Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late-onset small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2011; 37:191.</a></li><li><a class="nounderline abstract_t">Bahado-Singh RO, Kovanci E, Jeffres A, et al. The Doppler cerebroplacental ratio and perinatal outcome in intrauterine growth restriction. Am J Obstet Gynecol 1999; 180:750.</a></li><li><a class="nounderline abstract_t">Arbeille P, Roncin A, Berson M, et al. Exploration of the fetal cerebral blood flow by duplex Doppler--linear array system in normal and pathological pregnancies. Ultrasound Med Biol 1987; 13:329.</a></li><li><a class="nounderline abstract_t">Conde-Agudelo A, Villar J, Kennedy SH, Papageorghiou AT. Predictive accuracy of cerebroplacental ratio for adverse perinatal and neurodevelopmental outcomes in suspected fetal growth restriction: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52:430.</a></li><li><a class="nounderline abstract_t">Vollgraff Heidweiller-Schreurs CA, De Boer MA, Heymans MW, et al. Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 51:313.</a></li><li><a class="nounderline abstract_t">Akolekar R, Ciobanu A, Zingler E, et al. Routine assessment of cerebroplacental ratio at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. Am J Obstet Gynecol 2019; 221:65.e1.</a></li><li><a class="nounderline abstract_t">Vollgraff Heidweiller-Schreurs CA, van Osch IR, Heymans MW, et al. Cerebroplacental ratio in predicting adverse perinatal outcome: a meta-analysis of individual participant data. BJOG 2021; 128:226.</a></li><li><a class="nounderline abstract_t">Flood K, Unterscheider J, Daly S, et al. The role of brain sparing in the prediction of adverse outcomes in intrauterine growth restriction: results of the multicenter PORTO Study. Am J Obstet Gynecol 2014; 211:288.e1.</a></li><li><a class="nounderline abstract_t">Monteith C, Flood K, Pinnamaneni R, et al. An abnormal cerebroplacental ratio (CPR) is predictive of early childhood delayed neurodevelopment in the setting of fetal growth restriction. Am J Obstet Gynecol 2019; 221:273.e1.</a></li><li><a class="nounderline abstract_t">Smies M, Damhuis SE, Duijnhoven RG, et al. Study protocol for a randomized trial on timely delivery versus expectant management in late preterm small for gestational age pregnancies with an abnormal umbilicocerebral ratio (UCR): the DRIGITAT study. Trials 2022; 23:619.</a></li></ol></div><div id="topicVersionRevision">Topic 6768 Version 127.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407785" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26909664" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Consensus definition of fetal growth restriction: a Delphi procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32738107" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31520557" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Validation of Delphi procedure consensus criteria for defining fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11864679" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Intrauterine growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319247" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18438965" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sequence of cardiovascular changes in IUGR in pregnancies with and without preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23531326" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28433732" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The clinical significance of an estimated fetal weight below the 10th percentile: a comparison of outcomes of&lt;5th vs 5th-9th percentile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25004344" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Birth weight percentile and the risk of term perinatal death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26410205" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31226296" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fetal growth patterns in pregnancy-associated hypertensive disorders: NICHD Fetal Growth Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881956" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Introduction to the study of pre- and postnatal growth in humans: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3380603" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Congenital malformations and intrauterine growth retardation: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33426710" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fetal-TAPSE for Surveillance of Cardiac Function in Growth-Restricted Fetuses With a Portosystemic Shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28944967" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk for chromosomal aberrations in apparently isolated intrauterine growth restriction: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32039494" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prenatal sonographic features can accurately determine parental origin in triploid pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31891188" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Genetic syndromes associated with isolated fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33481528" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fetal Growth Restriction: ACOG Practice Bulletin, Number 227.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34058167" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Should prenatal chromosomal microarray analysis be offered for isolated fetal growth restriction? A French multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28889126" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chromosomal Microarray Analysis in Fetuses with Growth Restriction and Normal Karyotype: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35806993" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Genetic Aspects of Small for Gestational Age Infants Using Targeted-Exome Sequencing and Whole-Exome Sequencing: A Single Center Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36209938" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Should we offer prenatal exome sequencing for intrauterine growth restriction or short long bones? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36869857" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnostic yield of exome sequencing in isolated fetal growth restriction: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30196734" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The role of fetal growth restriction in the association between Down syndrome and perinatal mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35008459" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genetic Background of Fetal Growth Restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35934121" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pregnancy outcome of confined placental mosaicism: meta-analysis of cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7847559" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Confined placental mosaicism and intrauterine growth retardation: a case-control analysis of placentas at delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11125243" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Correlation of confined placental mosaicism with fetal intrauterine growth retardation. A case control study of placentas at delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34893980" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A systematic review of maternal TORCH serology as a screen for suspected fetal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217113" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32292902" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168789" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Practice Bulletin No. 132: Antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1887021" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : In utero analysis of fetal growth: a sonographic weight standard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24901276" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A revised birth weight reference for the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021697" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The risk of intrauterine fetal death in the small-for-gestational-age fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844190" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Monitoring of fetuses with intrauterine growth restriction: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23999424" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictable progressive Doppler deterioration in IUGR: does it really exist?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844191" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11876805" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18634130" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Progression of Doppler abnormalities in intrauterine growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34011892" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966988" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fetal umbilical artery flow velocity waveforms and placental resistance: pathological correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2679101" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of placental embolization on the umbilical arterial velocity waveform in fetal sheep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5101050" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The quantitative analysis of occlusive peripheral arterial disease by a non-intrusive ultrasonic technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5101050" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The quantitative analysis of occlusive peripheral arterial disease by a non-intrusive ultrasonic technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7426537" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fetal blood velocity waveforms in normal pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15746695" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reference ranges for serial measurements of umbilical artery Doppler indices in the second half of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34278615" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : ISUOG Practice Guidelines (updated): use of Doppler velocimetry in obstetrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20847548" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Differences in neonatal outcome in fetuses with absent versus reverse end-diastolic flow in umbilical artery Doppler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28613398" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fetal and umbilical Doppler ultrasound in high-risk pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25068564" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Defining the residual risk of adverse perinatal outcome in growth-restricted fetuses with normal umbilical artery blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1566783" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Middle cerebral artery flow velocity waveforms in normal and small-for-gestational-age fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30353583" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fetal Medicine Foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3518788" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Doppler ultrasound assessment of cerebral blood flow in the human fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900661" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Flow velocity waveforms of the fetal circulation preceding fetal death in a case of lupus anticoagulant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35026129" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical Opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035538" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neurodevelopmental outcome in 2-year-old infants who were small-for-gestational age term fetuses with cerebral blood flow redistribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21567514" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Changes in myocardial performance index and aortic isthmus and ductus venosus Doppler in term, small-for-gestational age fetuses with normal umbilical artery pulsatility index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32557921" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fetal cerebral Doppler changes and outcome in late preterm fetal growth restriction: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1683418" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ultrasonographic velocimetry of the fetal ductus venosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942494" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Qualitative venous Doppler waveform analysis improves prediction of critical perinatal outcomes in premature growth-restricted fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18548391" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The transitional phase of ductus venosus reversed flow in severely premature IUGR fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21465604" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Duration of persistent abnormal ductus venosus flow and its impact on perinatal outcome in fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35369904" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The role of the fetal biophysical profile in the management of fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18253968" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Biophysical profile for fetal assessment in high risk pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771977" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh&lt;1000 g.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23969791" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The role of growth trajectories in classifying fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31169958" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8521062" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Evaluation of intrauterine growth retardation in the fetus and neonate: are simple-minded methods good enough?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608100" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Standards for ultrasound fetal growth velocity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34627184" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Fetal growth velocity references from a Chinese population-based fetal growth study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29803819" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fetal growth velocity: the NICHD fetal growth studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35926648" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Unified standard for fetal growth velocity: the Eunice Kennedy Shriver National Institute of Child Health and Human Development Fetal Growth Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113225" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Doppler of the middle cerebral artery for the assessment of fetal well-being.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2952911" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cerebral and umbilical arterial blood flow velocity waveforms in normal and growth-retarded pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20617509" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late-onset small-for-gestational age fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10076158" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The Doppler cerebroplacental ratio and perinatal outcome in intrauterine growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3303590" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Exploration of the fetal cerebral blood flow by duplex Doppler--linear array system in normal and pathological pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29920817" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Predictive accuracy of cerebroplacental ratio for adverse perinatal and neurodevelopmental outcomes in suspected fetal growth restriction: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28708272" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30878322" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Routine assessment of cerebroplacental ratio at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32363701" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cerebroplacental ratio in predicting adverse perinatal outcome: a meta-analysis of individual participant data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813969" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The role of brain sparing in the prediction of adverse outcomes in intrauterine growth restriction: results of the multicenter PORTO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31226291" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : An abnormal cerebroplacental ratio (CPR) is predictive of early childhood delayed neurodevelopment in the setting of fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35915472" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Study protocol for a randomized trial on timely delivery versus expectant management in late preterm small for gestational age pregnancies with an abnormal umbilicocerebral ratio (UCR): the DRIGITAT study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
